Terminology Service for NFDI4Health
JSON

Ipilimumab

Go to external page http://purl.obolibrary.org/obo/NCIT_C2654

A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system. [ ]

Term info

Label

Ipilimumab

Synonyms
  • Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody
  • BMS-734016
  • IPILIMUMAB
  • Ipilimumab
  • MDX-010
  • MDX-CTLA4
  • Yervoy
  • ipilimumab
Subsets

NCIT_C116978, NCIT_C63923, NCIT_C128784, NCIT_C157711, NCIT_C116977, NCIT_C157712

ALT DEFINITION

A monoclonal antibody being studied in the treatment of certain types of cancer. Ipilimumab is made in the laboratory and binds to the molecule CTLA-4 on T cells (a type of white blood cell). Ipilimumab may block CTLA-4 and help the immune system kill cancer cells.

Accepted Therapeutic Use For

Unresectable or Metastatic Melanoma

CAS Registry

477202-00-9

Display Name

Ipilimumab

FDA UNII Code

6T8C155666

Has Target

http://purl.obolibrary.org/obo/NCIT_C17489

Legacy Concept Name

Anti-Cytotoxic_T-Lymphocyte-Associated_Antigen-4_Monoclonal_Antibody

NSC Code

720801, 732442

Preferred Name

Ipilimumab

Semantic Type

Amino Acid, Peptide, or Protein, Immunologic Factor

UMLS CUI

C1367202

code

C2654